

(43) International Publication Date
10 May 2013 (10.05.2013)(10) International Publication Number
WO 2013/067267 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/4439 (2006.01)
 C07D 405/14 (2006.01) A61K 31/4433 (2006.01)
 C07D 409/14 (2006.01) A61P 31/12 (2006.01)
 C07D 413/14 (2006.01) A61P 31/14 (2006.01)
 C07D 491/113 (2006.01)

(21) International Application Number:

PCT/US2012/063181

(22) International Filing Date:

2 November 2012 (02.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/555,056 3 November 2011 (03.11.2011) US
 61/600,089 17 February 2012 (17.02.2012) US
 61/637,961 25 April 2012 (25.04.2012) US

(71) Applicant (for all designated States except US):

THERAVANCE, INC. [US/US]; 901 Gateway
 Boulevard, South San Francisco, California 94080 (US).

(72) Inventors; and

(71) Applicants (for US only): **LONG, Daniel D.** [GB/US]; 10
 Sunview Drive, San Francisco, California 94131 (US).
MCKINNELL, Robert Murray [GB/US]; 321 Poplar
 Avenue, Millbrae, California 94030 (US). **JIANG, Lan**
 [CN/US]; 788 Santa Maria Lane, Foster City, California
 94404 (US). **LOO, Mandy** [US/US]; 2119 Imwalle Court,
 San Jose, California 95131 (US). **LEPACK, Kassandra**
 [CA/CA]; 30 Rosery Drive NW, Calgary, Alberta T2K 1L7
 (CA). **VAN ORDEN, Lori Jean** [US/US]; 3 Whitney
 Street, San Francisco, California 94131 (US). **OGAWA,**
Gavin [US/US]; 541 Hugo Street, San Francisco, Califor-

nia 94122 (US). **HUANG, Xiaojun** [CA/US]; 125 Con-
 nemara Way #35, Sunnyvale, California 94087 (US).
ZHANG, Weijiang [US/US]; 1282 North Montecito
 Drive, Concord, California 94521 (US).

(74) Agents: **HAGENAH, Jeffrey A.** et al.; Theravance, Inc.,
 901 Gateway Boulevard, South San Francisco, California
 94080 (US).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
 ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ROD -LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGMENT {2- [4- (BI PHENYL - 4 - YL) -
 1H - IMIDAZO - 2 - YL] PYRROLIDINE - 1 - CARBONYLMETHYL} AMINE



(57) Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.